Our portfolio of products
The company is engaged in a wide range of therapy areas including psychiatry and paediatrics. Flynn focuses on providing medicines for many groups of patients, often by re-discovering and re-energising already established drugs and branded pharmaceutical products. We seek to continue to deliver patient benefits through introducing new products, improving existing formulations or adding new indications.
Slenyto®
Formulation: Paediatric prolonged-release melatonin
Indications: Insomnia in children and adolescents aged 2-18 years with Autism Spectrum Disorder (ASD), and/or neurogenetic disorders with aberrant diurnal melatonin secretion and/or nocturnal awakenings, where sleep hygiene measures have been insufficient. Insomnia in children and adolescents aged 6-17 years with attention-deficit hyperactivity disorder (ADHD) where sleep hygiene measures have been insufficient.
Meflynate® XL
Formulation: Modified-release hard capsule
Indication: Methylphenidate is indicated as part of a comprehensive treatment programme for attention-deficit/hyperactivity disorder (ADHD) in children aged 6 years of age and over and adults when remedial measures alone prove insufficient.
Request a meeting
Send a virtual meeting request